Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Dam

Showing results (21-30 of 24) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 24 results.
The Science of the Total Environment|September 2, 2018
Temporal trends of persistent organic pollutants in Arctic marine and freshwater biotaFrank Rigét, Anders Bignert, Birgit Braune, et al.
The Science of the Total Environment|June 21, 2011
Temporal trends of Hg in Arctic biota, an updateFrank Rigét, Birgit Braune, Anders Bignert, et al.
Cancer Research|June 10, 2026
TNG917 is a Potent and Selective Inhibitor of Histone Lysine Methyltransferases EHMT1/2 that Enhances Anti-Tumor Immunity and Immunotherapy EfficacyAlvin Ziying Lu, Brian B Haines, Wenhai Zhang, et al.
Cancer Research|September 7, 2022
VRK1 Is a Synthetic-Lethal Target in VRK2-Deficient GlioblastomaJulie A Shields, Samuel R Meier, Madhavi Bandi, et al.
Pageof 3

Showing results (21-30 of 24) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
The Science of the Total Environment|September 2, 2018
Temporal trends of persistent organic pollutants in Arctic marine and freshwater biotaFrank Rigét, Anders Bignert, Birgit Braune, et al.
The Science of the Total Environment|June 21, 2011
Temporal trends of Hg in Arctic biota, an updateFrank Rigét, Birgit Braune, Anders Bignert, et al.
Cancer Research|June 10, 2026
TNG917 is a Potent and Selective Inhibitor of Histone Lysine Methyltransferases EHMT1/2 that Enhances Anti-Tumor Immunity and Immunotherapy EfficacyAlvin Ziying Lu, Brian B Haines, Wenhai Zhang, et al.
Cancer Research|September 7, 2022
VRK1 Is a Synthetic-Lethal Target in VRK2-Deficient GlioblastomaJulie A Shields, Samuel R Meier, Madhavi Bandi, et al.
Pageof 3